SLC16A12

Across TCGA pan-cancer cohorts, SLC16A12 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SLC16A12’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where SLC16A12 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC16A12 is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

KICH, COAD, and LUSC are the cancer types where SLC16A12 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC16A12 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	All	IV	−5.045	<.001	11	view →
COAD	All	III,IV	−0.397	<.001	11	view →
LUSC	Female	II,III,IV	−1.835	<.001	9	view →
KIRC	All	All	−1.082	<.001	9	view →
THCA	All	All	−0.892	<.001	7	view →
KIRP	Male	All	−2.184	<.001	6	view →
BRCA	All	III,IV	−1.291	<.001	6	view →
LUAD	All	All	−0.755	<.001	5	view →
STAD	All	All	−0.292	.003	5	view →
BLCA	Male	III,IV	−0.380	.012	4	view →
PRAD	All	All	−0.658	<.001	2	view →
READ	All	All	−0.583	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SLC16A12–KICH

Open the KICH breakdown →